PL1760088T3 - Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA) - Google Patents

Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA)

Info

Publication number
PL1760088T3
PL1760088T3 PL05019254T PL05019254T PL1760088T3 PL 1760088 T3 PL1760088 T3 PL 1760088T3 PL 05019254 T PL05019254 T PL 05019254T PL 05019254 T PL05019254 T PL 05019254T PL 1760088 T3 PL1760088 T3 PL 1760088T3
Authority
PL
Poland
Prior art keywords
molecules
tumour
present
relates
hla
Prior art date
Application number
PL05019254T
Other languages
English (en)
Inventor
Jörn Dengjel
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of PL1760088T3 publication Critical patent/PL1760088T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL05019254T 2005-09-05 2005-09-05 Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA) PL1760088T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05019254A EP1760088B1 (en) 2005-09-05 2005-09-05 Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules

Publications (1)

Publication Number Publication Date
PL1760088T3 true PL1760088T3 (pl) 2008-10-31

Family

ID=35170099

Family Applications (5)

Application Number Title Priority Date Filing Date
PL07007915T PL1806359T3 (pl) 2005-09-05 2005-09-05 Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II
PL07007914T PL1806358T3 (pl) 2005-09-05 2005-09-05 Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II
PL05019254T PL1760088T3 (pl) 2005-09-05 2005-09-05 Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA)
PL09011319T PL2135878T3 (pl) 2005-09-05 2006-09-05 Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami HLA klasy II
PL06791838T PL1922335T3 (pl) 2005-09-05 2006-09-05 Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami antygenów leukocytów ludzkich (HLA) klasy II

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL07007915T PL1806359T3 (pl) 2005-09-05 2005-09-05 Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II
PL07007914T PL1806358T3 (pl) 2005-09-05 2005-09-05 Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL09011319T PL2135878T3 (pl) 2005-09-05 2006-09-05 Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami HLA klasy II
PL06791838T PL1922335T3 (pl) 2005-09-05 2006-09-05 Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami antygenów leukocytów ludzkich (HLA) klasy II

Country Status (23)

Country Link
US (6) US10196432B2 (pl)
EP (6) EP1806358B1 (pl)
JP (1) JP5627180B2 (pl)
KR (3) KR101386790B1 (pl)
CN (3) CN105440119A (pl)
AT (5) ATE461214T1 (pl)
AU (2) AU2006289290B2 (pl)
BR (1) BRPI0615462A2 (pl)
CA (2) CA2929252A1 (pl)
CY (5) CY1107973T1 (pl)
DE (4) DE602005020046D1 (pl)
DK (5) DK1760088T3 (pl)
EA (1) EA013876B1 (pl)
ES (5) ES2341802T3 (pl)
HK (1) HK1220709A1 (pl)
HR (2) HRP20100128T1 (pl)
NO (1) NO340870B1 (pl)
NZ (2) NZ588813A (pl)
PL (5) PL1806359T3 (pl)
PT (5) PT1806358E (pl)
SI (5) SI1760088T1 (pl)
UA (1) UA98295C2 (pl)
WO (1) WO2007028574A2 (pl)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005020046D1 (de) * 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
NZ582823A (en) 2007-07-27 2012-04-27 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
HUE025636T2 (en) * 2007-07-27 2016-04-28 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
RS54204B1 (sr) 2007-07-27 2015-12-31 Immatics Biotechnologies Gmbh Nova imunoterapija protiv tumora mozga
UA100127C2 (ru) * 2007-08-20 2012-11-26 Онкотерапи Саенс, Инк. Пептид cdh3 и лекарственное средство, содержащее его
EP3085707B1 (en) 2007-11-01 2019-02-27 Mayo Foundation for Medical Education and Research Hla-dr binding peptides and their uses
ME02267B (me) 2008-03-27 2016-04-28 Immatics Biotechnologies Gmbh Nova imunoterapija protiv tumora nervnih ćelija i mozga
EP2113253B1 (en) 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
PT2119726E (pt) 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
DK2623517T3 (en) 2009-01-28 2015-11-23 Ind Tech Res Inst Urine and serum biomarkers associated with diabetic nephropathy
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
SG191154A1 (en) 2010-12-14 2013-07-31 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2012129514A1 (en) * 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
TWI714869B (zh) * 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
ES2900004T3 (es) 2013-08-05 2022-03-15 Immatics Biotechnologies Gmbh Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (NSCLC)
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
HRP20191671T1 (hr) 2014-05-09 2019-12-13 Immatics Biotechnologies Gmbh Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA50819A (fr) 2014-12-23 2021-04-07 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
IL301919A (en) 2015-03-27 2023-06-01 Immatics Biotechnologies Gmbh Innovative peptides and a combination of peptides for use in immunotherapy against various tumors
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
IL292697A (en) * 2015-06-19 2022-07-01 Immatics Biotechnologies Gmbh New peptides and their combination for use in immunotherapy and methods for creating supports for use against pancreatic cancer and other types of cancer
IL308735A (en) 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PT3319985T (pt) 2015-07-06 2021-01-06 Immatics Biotechnologies Gmbh Novos péptidos e combinação de péptidos para uso em imunoterapia do cancro do esófago e outros cancros
GB201512369D0 (en) 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IL292864A (en) 2015-08-28 2022-07-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides and supports for use in immunotherapy in certain types of cancer
PH12022551111A1 (en) 2015-10-05 2023-08-23 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
MY196837A (en) 2015-12-11 2023-05-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
JP7114477B2 (ja) 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
PE20181583A1 (es) 2016-03-01 2018-10-04 Immatics Biotechnologies Gmbh Peptido recombinante derivado de la proteina duoxa2
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) * 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
SG11201808196UA (en) * 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
SG10202110335PA (en) 2016-04-06 2021-10-28 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
MA43477A1 (fr) 2016-04-21 2019-05-31 Immatics Biotechnologies Gmbh Immunothérapie contre le mélanome et d'autres cancers
CR20200608A (es) 2016-04-21 2021-01-20 Immatics Biotechnologies Gmbh INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0551)
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
RU2630647C1 (ru) * 2016-05-27 2017-09-11 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
ES2987986T3 (es) * 2016-06-10 2024-11-18 Gadeta B V Nuevo método para identificar cadenas de receptores de células T delta (o células T gamma) o partes de estas que intervienen en una respuesta antitumoral o antiinfecciosa
TW202304970A (zh) 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
EA201991444A1 (ru) 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
AU2018212584B2 (en) 2017-01-27 2020-12-10 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
WO2018138257A1 (en) 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
TWI723247B (zh) * 2017-02-06 2021-04-01 中央研究院 重組蛋白及其用途
TW201841937A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於白血病和其他癌症免疫治療的新穎肽和肽組合物
TW201841934A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於治療癌症免疫治療的新穎肽及其肽組合物
MA49123A (fr) 2017-04-10 2020-03-25 Immatics Biotechnologies Gmbh Peptides et combinaison de peptides à utiliser en immunothérapie contre les leucémies et d'autres cancers
CR20210160A (es) 2017-04-10 2021-04-26 Immatics Biotechnologies Gmbh Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508)
WO2019007974A1 (en) 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
KR20200026898A (ko) 2017-07-07 2020-03-11 이매틱스 바이오테크놀로지스 게엠베하 Nsclc, sclc 등 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
EP3684196B1 (en) 2017-09-18 2024-09-04 S & P Ingredient Development, LLC Low sodium salt substitute with potassium chloride
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
DE102018108996B4 (de) 2018-02-09 2021-10-21 Immatics US, Inc. Verfahren zur Herstellung autologer T-Zellen
KR20200119840A (ko) 2018-02-09 2020-10-20 이매틱스 유에스 인코포레이티드 T 세포의 제조 방법
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
IL276839B1 (en) * 2018-02-27 2026-05-01 Gritstone Bio Inc Neoantigen identification using pan-allelic models
EP3539562A1 (en) * 2018-03-12 2019-09-18 Eberhard Karls Universität Tübingen Medizinische Fakultät Immunotherapeutic peptides
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
KR102215578B1 (ko) * 2019-03-28 2021-02-15 한국과학기술연구원 인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도
AU2020286756A1 (en) 2019-06-06 2022-01-27 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
CN110305209B (zh) * 2019-07-09 2022-09-13 福建医科大学附属第一医院 用于治疗恶性肿瘤的多肽及其作为疫苗的用途
WO2021019472A1 (en) * 2019-07-30 2021-02-04 University Health Network T cell receptors and methods of use thereof
EP3827840A1 (en) 2019-11-29 2021-06-02 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Teipp peptide variant and uses thereof
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
US11891427B2 (en) 2020-09-29 2024-02-06 Immatics Biotechnologies Gmbh Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
WO2024077601A1 (en) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Peptide vaccines against glioma and uses thereof
CN117720620B (zh) * 2023-12-13 2024-07-23 无锡市儿童医院 小分子多肽和其药物组合物、其制药用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212000B2 (en) * 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8258260B2 (en) * 1970-02-11 2012-09-04 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8211999B2 (en) * 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
GR66050B (pl) * 1977-09-20 1981-01-14 Licinvest Ag
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
YU44186B (en) 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4810781A (en) 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens
EP0636175A1 (en) * 1992-04-03 1995-02-01 La Jolla Cancer Research Foundation Decorin fragments and methods of inhibiting cell regulatory factors
EP0671926B1 (en) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
EP0725799A1 (en) * 1993-10-29 1996-08-14 Dana-Farber Cancer Institute, Inc. A novel tumor marker and novel method of isolating same
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
WO1996003144A1 (en) 1994-07-27 1996-02-08 The Council Of The Queensland Institute Of Medical Research Polyepitope vaccines
UY24367A1 (es) * 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
US6610821B1 (en) * 1996-07-12 2003-08-26 Mcgill University Compounds and methods for modulating endothelial cell adhesion
AU6241698A (en) * 1997-01-21 1998-08-07 Human Genome Sciences, Inc. Tace-like and matrilysin-like polypeptides
US6316213B1 (en) 1997-03-19 2001-11-13 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian, breast and lung cancer
EP1023445B1 (de) 1997-10-15 2005-08-17 Pharis Biotec GmbH Cadherin derived growth factor und seine verwendung
DE19757250A1 (de) * 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
US6746852B1 (en) * 1998-05-08 2004-06-08 Osi Pharmaceuticals, Inc. AGS proteins and nucleic acid molecules and uses thereof
DE19936563A1 (de) 1999-08-04 2001-02-08 Boehringer Ingelheim Int Tumorassoziiertes Antigen
DE19938583A1 (de) 1999-08-18 2001-02-22 Buehler Ag Verfahren und Vorrichtung zur Herstellung von kristallisationsfähigem Kunststoffmaterial
EP1290217A2 (en) * 2000-02-04 2003-03-12 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
WO2002008765A2 (en) * 2000-07-26 2002-01-31 Stanford University Basal cell markers in breast cancer and uses thereof
WO2002050103A2 (en) 2000-12-20 2002-06-27 Glaxosmithkline Biologicals S.A. Tumour-related antigens
AU2002303219A1 (en) 2001-03-30 2002-10-15 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US7049413B2 (en) * 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
JP2005500059A (ja) * 2001-08-13 2005-01-06 ダナ−ファーバー キャンサー インスティテュート インク． ペリオスチンに基づく診断アッセイ法
US6906036B2 (en) * 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
WO2003030836A2 (en) * 2001-10-12 2003-04-17 Case Western Reserve University Neuronal regeneration
WO2003068940A2 (en) * 2002-02-14 2003-08-21 Curagen Corporation Complexes and methods of using same
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
WO2004014867A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Matrix metalloproteinase inhibitors and methods for identification of lead compounds
CA2500687A1 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1560597A4 (en) * 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED CANCER GENES, POLYPEPTIDES CODED THEREIN, AND METHOD OF USE THEREOF
JP2007504842A (ja) * 2003-05-29 2007-03-08 ミレニアム ファーマシューティカルズ， インコーポレイテッド 乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法
EP1646648A2 (en) * 2003-07-15 2006-04-19 Genova Ltd. Secreted polypeptide species reduced in cardiovascular disorders
EP1757940A1 (en) 2005-08-26 2007-02-28 Cézanne S.A.S. In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
DE602005020046D1 (de) * 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
SI1760089T1 (sl) * 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
EP1795599A1 (en) * 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells

Also Published As

Publication number Publication date
JP5627180B2 (ja) 2014-11-19
EA013876B1 (ru) 2010-08-30
WO2007028574A2 (en) 2007-03-15
ATE461214T1 (de) 2010-04-15
EP2135878B1 (en) 2011-11-09
ES2341802T3 (es) 2010-06-28
CA2929252A1 (en) 2007-03-15
PT2135878E (pt) 2012-01-05
PL1806358T3 (pl) 2010-08-31
US10196432B2 (en) 2019-02-05
SI1806359T1 (sl) 2010-06-30
EA200800677A1 (ru) 2008-08-29
KR101386790B1 (ko) 2014-04-21
EP1760088A1 (en) 2007-03-07
EP1806358A3 (en) 2007-10-03
AU2010236029B2 (en) 2012-06-28
UA98295C2 (ru) 2012-05-10
PL1806359T3 (pl) 2010-08-31
PT1922335E (pt) 2010-03-03
CY1110187T1 (el) 2015-01-14
DE602005005196D1 (de) 2008-04-17
HK1183678A1 (en) 2014-01-03
US20080206216A1 (en) 2008-08-28
CN101287754A (zh) 2008-10-15
HRP20110981T1 (hr) 2012-02-29
EP1922335A2 (en) 2008-05-21
ES2373907T3 (es) 2012-02-10
DK2135878T3 (da) 2012-02-27
ATE451388T1 (de) 2009-12-15
CY1109849T1 (el) 2014-09-10
HRP20100128T1 (hr) 2010-04-30
US7833970B2 (en) 2010-11-16
CN103059104A (zh) 2013-04-24
PT1806359E (pt) 2010-05-25
CY1112186T1 (el) 2015-12-09
DE602005020047D1 (de) 2010-04-29
CN101287754B (zh) 2013-02-13
ATE461215T1 (de) 2010-04-15
SI1922335T1 (sl) 2010-04-30
NO20081683L (no) 2008-04-04
WO2007028574A9 (en) 2008-05-02
PT1760088E (pt) 2008-05-14
KR20080052643A (ko) 2008-06-11
CY1110051T1 (el) 2015-01-14
NO340870B1 (no) 2017-07-03
US7807642B2 (en) 2010-10-05
AU2006289290B2 (en) 2010-11-25
SI1806358T1 (sl) 2010-06-30
US20080206218A1 (en) 2008-08-28
HK1220709A1 (zh) 2017-05-12
CA2621389C (en) 2016-07-19
PL2135878T3 (pl) 2012-06-29
ES2337399T3 (es) 2010-04-23
ES2302546T3 (es) 2008-07-16
ATE388164T1 (de) 2008-03-15
CA2621389A1 (en) 2007-03-15
AU2010236029A1 (en) 2010-11-18
US20160115212A1 (en) 2016-04-28
EP1806358B1 (en) 2010-03-17
DK1760088T3 (da) 2008-06-09
US7833969B2 (en) 2010-11-16
DE602006011030D1 (de) 2010-01-21
KR101386827B1 (ko) 2014-04-17
US10618945B2 (en) 2020-04-14
SI2135878T1 (sl) 2012-03-30
PL1922335T3 (pl) 2010-05-31
CY1107973T1 (el) 2013-09-04
EP1806359B1 (en) 2010-03-17
WO2007028574A3 (en) 2007-05-24
KR20130019034A (ko) 2013-02-25
CN103059104B (zh) 2015-10-28
SI1760088T1 (sl) 2008-06-30
US20080206217A1 (en) 2008-08-28
PT1806358E (pt) 2010-05-28
DE602005005196T2 (de) 2008-06-26
EP1760088B1 (en) 2008-03-05
DK1922335T3 (da) 2010-04-19
KR101386355B1 (ko) 2014-04-17
DK1806359T3 (da) 2010-06-14
ATE532795T1 (de) 2011-11-15
EP2138509A1 (en) 2009-12-30
EP2135878A1 (en) 2009-12-23
KR20130019033A (ko) 2013-02-25
NZ566104A (en) 2011-04-29
BRPI0615462A2 (pt) 2011-05-17
CN105440119A (zh) 2016-03-30
US20080207520A1 (en) 2008-08-28
ES2341295T3 (es) 2010-06-17
EP1806359A1 (en) 2007-07-11
NZ588813A (en) 2011-06-30
JP2010502173A (ja) 2010-01-28
DK1806358T3 (da) 2010-06-28
EP1806358A2 (en) 2007-07-11
AU2006289290A1 (en) 2007-03-15
US20100040590A1 (en) 2010-02-18
DE602005020046D1 (de) 2010-04-29
EP1922335B1 (en) 2009-12-09

Similar Documents

Publication Publication Date Title
PL1806359T3 (pl) Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II
SI1922334T1 (sl) S tumorjem povezani peptidi, ki se veĹľejo na molekule antigena humanih levkocitov (HLA), razreda I in II, ter ustrezno cepivo proti raku
SI1642905T1 (sl) Imunogeni T-pomagalni epitop iz humanega tumornega antigena in imunoterapevtski postopki, ki uporabljajo navedeni epitop